智通财经APP讯，复星医药(02196)发布公告，上海复星医药(集团)股份有限公司(以下简称“本公司”)控股子公司复星医药(徐州)有限公司于近日收到国家药品监督管理局关于同意 CMC-2310 口溶膜(以下简称“CMC-2310”)用于成人及 13 岁以上儿童患者的精神分裂症治疗开展临床试验的批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.